Sampo plc, stock exchange release, 10 September 2025 at 8:30 am EEST Sampo plc’s share buybacks 9 September 2025 On 9 September 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code) 3,7489.80AQEU 115,8959.78CEUX 39,3259.78TQEX 168,5629.78<td style="width: ...

Financial Reporting Schedule - Verkkokauppa.com Oyj will hold its Annual General Meeting on April 14, 2026, as a virtual-only event [1] - The company will publish its financial statements for the year 2025 on February 12, 2026, with an annual reporting package available during the week starting March 9, 2026 [4] - Interim reports for 2026 will be released on April 23, July 16, and October 22, with the financial statements for 2026 scheduled for February 12, 2027 [4] Company Overview - Verkkokauppa.com was founded in 1992 and has been operating online since its inception [3] - The company's revenue for 2024 was EUR 468 million, and it employs approximately 600 people [3] - Verkkokauppa.com is recognized as an e-commerce pioneer in Finland, offering rapid delivery services and a customer-centric approach [2]

Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025. Euronext Amsterdam announced the results of its review of the AMX index, which comprises 25 companies based on free-float market capitalization and liquidity. This marks Pharming’s return to the AMX index, reflecting the Company’s strong growth ...

MCH GROUP INCREASES HALF-YEAR PROFIT AND STRENGTHENS PROFITABILITY MCH Group closed the first half of 2025 with an increase in earnings. Despite lower revenues, profitability improved further – clear evidence of the implementation of efficiency measures. For the third consecutive time, following years of losses, MCH Group reported a positive half-year result. Despite a slight decline in revenue, profitability increased markedly: net profit amounted to CHF 5.3 million, operating income to CHF 222.4 million ...

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patientsIntention to reduce ~9,000 roles globally with the expectation to deliver DKK 8bn of annualised savings by the end of 2026One-off restructuring costs of DKK 8bn leading to an updated full-year 2025 operating profit growth outlook of 4–10% at CER Bagsværd, Denmark, 10 September 2025 – Novo Nordisk today announced a company-wide transformation to simplif ...

On 9 September 2025, AS LHV Group carried out an issue of Tier 2 subordinated notes in the total nominal amount of EUR 80,000,000 (the “Notes”) in the international markets. The settlement date of the Notes is 16 September 2025. The Notes are issued in bearer form with a denomination of EUR 100,000, with increments of EUR 1,000. The Notes mature on 16 September 2035 and have a first call date on 16 September 2030. Until the first call date, the Notes bear interest at a fixed rate of 5.5% per annum, payable ...

Coop Pank’s financial results in August 2025: In August, number of the bank's clients increased by 1,700 and number of active clients decreased by 300. By the end of the month number of clients reached 221,000 and number of active clients reached 103,800. Over the year, customer base has grown by 11%. Volume of the bank's customer deposits decreased by 4 million euros and reached 1.92 billion euros by the end of month. Deposits of corporate customers decreased by 6 million euros and deposits of private cust ...

TGS’ presentation for the Pareto Securities Energy Conference 2025 is available on www.newsweb.no or TGS’ website www.tgs.com. CEO Kristian Johansen will present today at 15:55 CEST. For more information, visit TGS.com or contact: Bård Stenberg VP IR & Communication Mobile: +47 992 45 235 investor@tgs.com Attachment Pareto Securities Energy Conference 2025 ...

Faraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company Status Faraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company Status Upholding its principles of “no further reverse stock splits” and prudent equity issuances, the Company is committed to ...

Core Viewpoint - Dianthus Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of 6,487,879 shares of common stock at $33.00 per share, along with pre-funded warrants for 1,112,121 shares at $32.999 each, aiming to raise approximately $251 million before expenses [1][2]. Group 1: Offering Details - The offering includes a total of 6,487,879 shares of common stock priced at $33.00 each and pre-funded warrants for 1,112,121 shares priced at $32.999 each, with an exercise price of $0.001 per share [1]. - The expected gross proceeds from the offering are approximately $251 million, excluding underwriting discounts and commissions [1]. - The offering is set to close on September 11, 2025, subject to customary closing conditions, and underwriters have a 30-day option to purchase an additional 1,140,000 shares [1]. Group 2: Use of Proceeds - Dianthus intends to utilize the net proceeds from the offering to advance its preclinical and clinical development activities, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [5].